Research Article
Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
Table 3
Characteristics of pathological manifestation of nontype 1 ROP receiving treatment.
| Characteristics | Nontype 1 treated eyes (N = 65) | N | % |
| Zone | I | 2 | 3.1 | II | 63 | 96.9 | Posterior II | 5 | 7.7 | Periphery II | 58 | 89.2 |
| Stage | 1 | 2 | 3.1 | 2 | 40 | 61.5 | 3 | 23 | 35.4 |
| Plus diseaseα | − | 7 | 10.8 | ± | 58 | 89.2 |
| Reasons | Preplus | 58 | 89.2 | Ridge aggravation | 22 | 33.8 | Contralateral eye | 9 | 13.8 | Follow-up time ≥ PMA44w | 8 | 12.3 | Logistical considerations | 4 | 6.2 |
|
|
α±, referred to preplus diseases.
|